Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aripiprazole (Bostal Pharma)
- Development stage
- Unknown
- Lead developer
- Bostal Pharma
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
R&D 061 LAI is a long-acting injectable (LAI) formulation of the atypical antipsychotic **aripiprazole**, developed by **Bostal Drug Delivery** (also known as Bostal Pharma). The drug is designed for intramuscular administration with dosing schedules of once monthly (1M) and once every three months (3M). Aripiprazole functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors, a profile that helps stabilize neurotransmitter activity in the brain. R&D 061 LAI utilizes Bostal's proprietary drug delivery technology to provide sustained therapeutic plasma concentrations, aiming to improve treatment adherence and clinical outcomes for patients with schizophrenia and other neuroscience-related disorders. It is currently in Phase 3 clinical development.
- Other names
- aripiprazole long-acting injectablearipiprazole extended-release injection
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on aripiprazole (Bostal Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aripiprazole (Bostal Pharma).